Financial Results | Lyell Immunopharma 2025 Q1 Revenue USD 0.01 Million Net Loss USD 52.20 Million

Lyell Immunopharma(LYEL) posted the Q1 of its 2025 financial results on 5/13/2025, reporting total revenue of USD 0.01 million in the first quarter, up 133.33% from USD 0.00 million year over year, reporting net loss of USD 52.20 million in the first quarter, narrowing 13.96% from USD -60.67 million year over year. The EPS is USD -0.18 in the frist quater, compare with USD -0.24 last period.

[Detailed Data]

Million USD	Q1 2025	Q4 2024	Q3 2024	Q4 2024
Total Revenue	0.01	0.01	0.03	0.01
Gross Profit	0.01	0.01	0.03	0.01
Total Operating Expenses	53.51	196.24	44.57	196.24
Operating Income	-53.51	-196.23	-44.54	-196.23
Net Income	-52.20	-191.94	-44.58	-191.94
Net Income Attributable to Common Shareholders	-52.20	-191.94	-44.58	-191.94
EPS(USD)	-0.18	-0.6509	-0.17	-0.6509

[Company Profile]
Lyell Immunopharma, Inc. was incorporated in Delaware in June 2018. The company is a clinical-stage cell therapy company expecting to enter pivotal trials in 2025 and advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor T-cell product candidates for patients with hematologic malignancies and solid tumors. The company is pioneering novel approaches designed to generate T cells that drive long-lasting clinical responses. The patient’s living cells are the starting point for the company investigational CAR T-cell therapies, and the company enhance with innovative CAR constructs, technology and manufacturing protocols.